Effects of Aspirin, Nonsteroidal Anti-inflammatory Drugs, Statin, and COX2 Inhibitor on the Developments of Urological Malignancies: A Population-Based Study with 10-Year Follow-up Data in Korea / Journal of the Korean Cancer Association, 대한암학회지

PURPOSE: The purpose of this study was to determine the impact of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), statin, and cyclooxygenase 2 (COX-2) inhibitor on the development of kidney, prostate, and urothelial cancers by analyzing the Korean National Health Insurance Service–National Sample Cohort (NHIS-NSC) database. MATERIALS AND METHODS: Among a representative sample cohort of 1,025,340 participants in NHIS-NSC database in 2002, we extracted data of 799,850 individuals who visited the hospital more than once, and finally included 321,122 individuals aged 40 and older. Following a 1-year washout period between 2002 and 2003, we analyzed 143,870 (male), 320,861 and 320,613 individuals for evaluating the risk of prostate cancer, kidney cancer and urothelial cancer developments, respectively, during 10-year follow-up periods between 2004 and 2013. The medication group consisted of patients prescribed these drugs more than 60% of the time in 2003. To adjustfor various parameters of the patients, a multivariate Cox regression model was adopted. RESULTS: During 10-year follow-up periods between 2004 and 2013, 9,627 (6.7%), 1,107 (0.4%), and 2,121 (0.7%) patients were diagnosed with prostate cancer, kidney cancer, and urothelial cancer, respectively. Notably, multivariate analyses revealed that NSAIDs significantly increased the risk of prostate cancer (hazard ratio [HR], 1.35). Also, it was found that aspirin (HR, 1.28) and statin (HR, 1.55) elevated the risk of kidney cancer. No drugs were associated with the risk of urothelial cancer. CONCLUSION: In sum, our study provides the valuable information for the impact of aspirin, NSAID, statin, and COX-2 inhibitor on the risk of prostate, kidney, and urothelial cancer development and its survival outcomes.

The Prevalence and Features of Korean Gout Patients Using the National Health Insurance Corporation Database

OBJECTIVE: We wanted to evaluate the prevalence of gout and its features in Korean people using the National Health Insurance Corporation (NHIC) database. METHODS: Using the NHIC database from 2001 to 2008, we selected the gout patients who were coded as having gout as a main diagnosis. From the total number of gout patients, we evaluated the prevalence of gout and its features. RESULTS: The prevalence of gout prevalence was 0.171% in 2001 and 0.397% in 2008, and there was a 2.317 fold increased during over the 7 years. In 2008, the percentage of fifth and sixth decade patients was 48.5% and that of the male patients were 89.8% of the total gout patients. The increasing rate of the prevalence of gout during the same period was also higher in males (the male vs. female ratio was 5.3:1 in 2001 and 8.8:1 in 2008). The gout prevalence increased year by year to the eighth decade, and the peak prevalence age group was the ninth decade in 2001, the eighth decade in 2002-2005 and the seventh decade in 2006-2008. The prevalence ratio of 2008 to 2001 was higher for the males and the younger age group; that of third decade for males was 9.87 , which was over the 10 times higher compared to that of the ninth decade (9.87 vs. 0.89, respectively). CONCLUSION: The prevalence of gout in 2008 using the NHIC database was 0.397%, so the prevalence of gout increased 2.317 fold over the 7 years, and nearly 90% of the gout patients were male. The increasing rate of gout prevalence was higher in the males and the younger age group.